Oncogenic KRAS (KRAS*) contributes to many cancer hallmarks. In colorectal cancer,
KRAS* suppresses antitumor immunity to promote tumor invasion and metastasis. Here, we …

Oncogenic KRAS has been previously identified to act in a cell-intrinsic manner to modulate
multiple biological functions of colorectal cancer (CRC). Here, we demonstrate a cell …

Ras signaling originates from transient nanoscale compartmentalized regions of the plasma
membrane composed of specific proteins and lipids. The highly specific lipid composition of …

Background Activating mutations in KRAS frequently occur in colorectal cancer (CRC)
patients, leading to resistance to EGFR-targeted therapies. Methods To better understand …

Human colorectal cancer (CRC) is a major cause of cancer mortality and frequently harbors
activating mutations in the KRAS gene. To understand the role of oncogenic KRAS in CRC …

The KRAS gene is one of the most frequently mutated oncogenes in human cancer and
gives rise to two isoforms, KRAS4A and KRAS4B. KRAS post-translational modifications …

While important strides have been made in cancer therapy by targeting certain oncogenes,
KRAS, the most common among them, remains refractory to this approach. In recent years, a …

The high morbidity and mortality of colorectal cancer (CRC) remain a worldwide challenge,
despite the advances in prevention, diagnosis, and treatment. RAS alterations have a …

Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

The ability to adapt to low-nutrient microenvironments is essential for tumor cell survival and
progression in solid cancers, such as colorectal carcinoma (CRC). Signaling by the NF-κB …